Cellular and humoral immune responses against cancer: implications for cancer vaccines.
The key issue in tumor immunology is to identify antigens as target structures for a cancer-selective immunological attack in the tumor-bearing host, resulting in tumor rejection. There is a growing detailed understanding of structural and regulatory gene alterations giving rise to candidate rejection antigens and peptides in tumor cells. As well as reviewing the development of new adjuvant and recombinant vector systems, new approaches are suggested for the construction of cancer vaccines.
Knuth
A
A
Klinikum, Johannes-Gutenberg-Universität, Mainz, Germany.
Wölfel
T
T
Meyer zum Büschenfelde
K H
KH
D000818:Animals; D000912:Antibodies, Neoplasm / Q000276:immunology; D000917:Antibody Formation; D000951:Antigens, Neoplasm / Q000276:immunology; D001500:BCG Vaccine; D016207:Cytokines / Q000096:biosynthesis; D005732:Gangliosides / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D008222:Lymphokines / Q000096:biosynthesis; D051379:Mice; D009369:Neoplasms / Q000276:immunology* / Q000517:prevention & control; D009374:Neoplasms, Experimental / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014612:Vaccines / Q000276:immunology*; D014614:Vaccines, Synthetic
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D016207:Cytokines; D005732:Gangliosides; D008222:Lymphokines; D014612:Vaccines; D014614:Vaccines, Synthetic